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Abstract
Introduction: A wide variety of fractionation schedules have been employed for the treatment of early glottic
cancer. The aim is to report our 10-year experience of using hypofractionated radiotherapy with 55Gy in 20
fractions at 2.75Gy per fraction.
Methods: Patients treated between 2004 and 2013 with definitive radiotherapy to a dose of 55Gy in 20 fractions
over 4 weeks for T1/2 N0 squamous cell carcinoma of the glottis were retrospectively identified. Patients with prior
therapeutic minor surgery (eg. laser stripping, cordotomy) were included. The probabilities of local control, ultimate
local control (including salvage surgery), regional control, cause specific survival (CSS) and overall survival (OS) were
calculated.
Results: One hundred thirty-two patients were identified. Median age was 65 years (range 33–89). Median follow
up was 72 months (range 7–124). 50 (38 %), 18 (14 %) and 64 (48 %) of patients had T1a, T1b and T2 disease
respectively. Five year local control and ultimate local control rates were: overall - 85.6 % and 97.3 % respectively,
T1a - 91.8 % and 100 %, T1b - 81.6 and 93.8 %, and T2 - 80.9 % and 95.8 %. Five year regional control, CSS and OS
rates were 95.4 %, 95.7 % and 78.8 % respectively. There were no significant associations of covariates (e.g. T-stage,
extent of laryngeal extension, histological grade) with local control on univariate analysis. Only increasing age and
transglottic extension in T2 disease were significantly associated with overall survival (both p <0.01). Second primary
cancers developed in 17 % of patients. 13 (9.8 %) of patients required enteral tube feeding support during
radiotherapy; no patients required long term enteral nutrition. One patient required a tracheostomy due to a
non-functioning larynx on long term follow up.
Conclusions: Hypofractionated radiation therapy with a dose of 55Gy in 20 fractions for early stage glottic cancer
provides high rates of local control with acceptable toxicity.
Introduction
Larynx cancer remains a common head and neck cancer,
with 2360 cases diagnosed within the UK in 2011 [1]. The
vocal cords (glottis) are the most commonly involved
subsite, representing approximately 75 % of larnynx car-
cinoma [2]. Glottic carcinoma commonly presents early,
and unlike many other head and neck cancer subsites,
paucity of lymphatic drainage in the glottis mucosa
conveys a low risk of lymphatic dissemination [3]. The
aim of treatment for early glottic carcinoma is generally
cure with laryngeal preservation and adequate/good voice
quality. Definitive radiotherapy and transoral laser resec-
tion are both widely employed, with the choice depending
on tumour factors including involvement of one or both
cords, anterior commissure involvement, physician choice
and expertise and patient preference. Reviews of the out-
comes of radiotherapy and laser resections suggests
comparable local control, and survival with similarly
low risks of major complications [3, 4]; local control
may be inferior after laser excision in cases with anterior
commisure involvement [3]. Voice quality following laser
resection is related to the extent of the resection [3, 5]. In
the modern era, open partial laryngectomies are usually
reserved to salvage local recurrences which remain suit-
able for laryngeal preservation [6].
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A wide range of radiotherapy dose-fractionation sched-
ules have been employed for the treatment of early glottic
carcinoma [7–12]. In 2006, the Royal College of Radiolo-
gists (RCR) Radiotherapy Dose Fractionation guidance
[13] commented that both conventional fractionation
(2Gy per fraction) and hypofractionated schedules (16–20
fractions) were effective, although ‘noting that short frac-
tionation regimens remain the minority practice inter-
nationally, with a less robust evidence based than that for
conventional treatment’. Recommended schedules in-
cluded 64–70Gy in daily 2Gy fractions over 6.5–7 weeks,
54–55Gy in 20 daily fractions over 4 weeks, and 50–
52.5Gy in 16 daily fractions over 3 weeks for small volume
disease only [13]. In a similar era, regimens employing
2.25Gy per fraction (to a total dose of 63–65.25Gy have
also been recommended [7, 8].
Hypofractionation to minimise potential for tumour
repopulation during radiotherapy is particularly appeal-
ing for early larynx in view of small field sizes, poten-
tially allowing larger doses per fraction without excessive
late morbidity [9]. Audits of UK practice have revealed
that the use of larger doses per fraction, such as 2.75Gy
in schedules of 55Gy in 20 fractions, are employed to
treat a substantial proportion of patients within the UK
for early larynx cancer [14, 15]. However, as highlighted
in the RCR guidance [13] there is only limited published
data documenting the efficacy of the more hypofractio-
nated schedules. Importantly, these is little data available
to support the use of similar schedules for the treatment
of T2 glottic carcinoma, with the two main series report-
ing the use of hypofractionated schedules with fraction
sizes >2.5Gy included only T1 disease [11, 12]. Here we
report our 10 year experience of treating T1/2 glottic
carcinoma with 55Gy in 20 fractions over 4 weeks.
Methods
This is a single centre retrospective study. Patients treated
between 2004 and 2013 with definitive radiotherapy for
glottis laryngeal cancer were retrospectively identified
from radiotherapy databases and electronic patient notes.
Inclusion criteria were: biopsy proven invasive squamous
cell carcinoma of the glottis, T1 or T2 N0 disease,
intended definitive radiotherapy with a prescribed dose of
55Gy in 20 fractions over 4 weeks; patients with prior
therapeutic minor surgery (eg. laser stripping, cordotomy)
were included.
Radiotherapy technique
Patients were immobilised with a beam directional shell.
Conventional X-ray simulation was in the initial part of
the study period until 2006; this was subsequently re-
placed by virtual CT simulation. The majority of treat-
ment was delivered using lateral opposed photon fields.
Standard field borders in treatment protocols were
similar to those previously described [16]: 1) superior:
mid thyroid notch, 2) inferior: bottom of cricoid car-
tilage, 3) anterior: 1 cm anterior to skin of neck, 4)
posterior: anterior to vertebral body. Elective neck
radiotherapy was not used for any patient. When
shoulder position would have obstructed the delivery
of lateral opposed fields, an anterior oblique arrange-
ment was used. The CT data was loaded into the
Helax-TMS VG-1B® (Nucleotron, Colombia, USA) treat-
ment planning system (prior to 2008) and onto Oncentra
MasterPlan® (Nucleotron, Colombia, USA) after 2008.
Bolus was used at clinicians’ discretion, and was gen-
erally considered for disease of the anterior cord/
commissure and if the patient’s neck was thin. Treat-
ment was planned with 6MV photons, and prescribed
to the International Commission on Radiation Units
and Measurements (ICRU) reference point in accord-
ance with the ICRU 50 recommendations [17], to a
total dose of 55Gy in 20 fractions, 2.75Gy per frac-
tion, delivered 5 days per week over 4 weeks. Treat-
ment delivery was with a 6MV linear accelerator with
1 cm multileaf collimators (Elekta, Sweden).
Follow up
Patients were typically reviewed weekly during treatment
and then 6–8 weekly for 2 years post-treatment, with
further follow up at increasing intervals for at least 5
years.
Biologically effective dose calculation
The tumour biologically effective dose (BED) was calcu-
lated using the standard linear quadratic equation [18]:
BED ¼ D 1þ d=α=βð Þð Þ− Ln 2ð Þ=αð Þ T−tkð Þ=tp
  
In which: D = total dose (Gy), d = dose per fraction
(Gy), α/β = linear (α) and quadratic (β) components of
the linear quadratic model (Gy); T = overall treatment
time (days); tk = onset of accelerated repopulation time
(days); tp = average doubling time during accelerated re-
population (days). The parameters used for calculation
of tumour BEDs were derived from prior radiobiological
studies [18–20]: α/β = 10Gy; α = 0.3Gy−1; tk = 22 days;
tp = 3 days. For late effects the standard linear quadratic
equation was used [18, 21]:
BED ¼ D 1þ d=α=βð Þð Þ
In which for late responding tissues α/β = 3Gy [21].
Statistical analysis
Statistical analysis was performed using SPSS version 16
(IBM, USA), STATA version 10 (Statacorp, USA), and
Prism version 6 (Graphpad, USA). Survival and recur-
rence outcomes were calculated from the last date of of
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radiotherapy treatment. The following endpoints were
used for assessment: local control, ultimate local control
(including salvage treatment) regional control, cause
specific survival (CSS) overall survival (OS), and were
analysed using Kaplan–Meier product limit curves. Uni-
variate Cox proportional hazards regression analysis was
performed for the following factors: age, gender, smok-
ing, alcohol consumption, histological differentiation, T
stage (T1a versus T1b versus T2), anterior commissure
involvement, supra-or sub-or trans-glottic extension,
cord mobility, and prior laser therapy.
Results
Patient and treatment characteristics
One hundred thirty-two patients were identified who
fulfilled the inclusion criteria for inclusion in this retro-
spective study. Patient, tumour and treatment character-
istics are summarised in Table 1. The median follow-up
time was 72 (range 7 to 124) months. 68 (52 %) and 64
(48 %) of patients had T1 and T2 disease respectively; all
patients had N0 disease. All patients had biopsy proven
squamous cell carcinoma. 112/132 (85 %) had under-
gone a contrast-enhanced staging CT of larynx, 2/132
(1.5 %) had undergone an MRI larynx, and 18/132 (14
%) did not undergo cross sectional imaging of the larynx
(comprising 16 patients with T1a, one patient with T1b
and one patient with T2 disease). 14 patients had under-
gone prior laser treatment for early glottic carcinoma;
radiotherapy was delivered to 4 of these patients due to
clinical evidence of residual disease in situ following
laser treatment, and to 10 patients following biopsy
proven recurrence after prior laser therapy. All patients
received the intended prescribed radiotherapy dose of
55Gy in 20 fractions in 2.75Gy per fraction. The calcu-
lated tumour BED of the schedule is 67Gy. Median dur-
ation of radiotherapy was 28 days (range 25 to 35 days).
Treatment duration was greater than 28 days in 2 pa-
tients (32 and 35 days); reason for delay was not docu-
mented for one patient and due to patient compliance
for the other.
Disease and survival outcomes
131/132 (99 %) of patients had a complete clinical re-
sponse to treatment; the patient with persistent disease
underwent a salvage total laryngectomy. Five year actuar-
ial local control rates were as follows: overall 85.6 %, T1a
91.8 %, T1b 81.6 % and T2 80.9 %. Ultimate local control
rates (including successful salvage treatment) were: overall
97.3 %, T1a 100 %, T1b 93.8 % and T2% 95.8 %. Overall 5
year neck (regional) control was 95.4 %.
A total of 20/132 (15) patients experienced disease
recurrence after the initial complete clinical response;
median time to recurrence was 23 months (5 to 73).
The patterns of recurrence are summarised in Table 2.
Fourteen patients experienced local recurrence only
after a median of 22 months (range 5–72) post radio-
therapy. Of isolated local recurrences, 13/14 (93 %)
were at the laryngeal subsite of the original primary
tumour. Six patients developed regional neck recur-
rence, three of which was in combination with recur-
rence at the primary subsite.
Table 2 includes details of salvage treatments. A total
of 18 patients underwent salvage surgery. 3 patients with
recurrence did not undergo surgical salvage due to
Table 1 Patient and disease characteristics (n = 132)
Characteristics N of patients
(range or %)
Mean Age 65 (33–89)
Sex Male 117 (89 %)
Female 15 (11 %)
Smoking Never 17 (13 %)
Current or former 106 (80 %)
Unknown 9 (7 %)
Alcohol Use (moderate or heavy) None 16 (12 %)
Current or former 85 (64 %)
Unknown 31 (23 %)
Performance status 0–1 116 (88 %)
2 4 (3 %)
3 2 (2 %)
Unknown 11 (8 %)
T Stage T1a 50 (38 %)
T1b 18 (14 %)
T2 64 (48 %)
Histology Squamous cell 132 (100 %)
Verrucous 1
Papillary cell 1
Spindle 1
Extension Subglottic 34 (26 %)
Supraglottic 17 (13 %)
Transglottic 5 (4 %)
Anterior commissure involvement Involved 59 (45 %)
Non involved 72 (55 %)
Missing 1 (1 %)
Cord mobility Mobile 21 (16 %)
Impaired 3 (2 %)
Grade Well 32 (24 %)
Moderate 49 (37 %)
Poor 15 (11 %)
Unknown 36 (27 %)
Prior laser Yes 14 (11 %)
No 118 (89 %)
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limited performance status, patient choice and death
from intercurrent illness. 12 of the 18 patients (67 %)
who underwent salvage surgery are disease free and
alive; 3 of 12 have a functional larynx.
Five year CSS and OS were 95.7 % and 78.8 %
respectively. A total of 36 (27.2 %) deaths occurred during
follow up. The cause of deaths were: recurrent larynx can-
cer in 7 (5.3 %), second cancers in 14 (10.6 %) and death
with other reasons in 15 (11.3 %) patients. Figure 1 illus-
trates 5-year local control, cause specific survival and
overall survival outcomes.
Univariate analysis of covariates did not reveal any sig-
nificant association with local control (all p >0.05). Only
two covariates were significantly associated with overall
survival: increasing age (p <0.01) and transglottic exten-
sion in T2 disease compared to T1 disease (Hazard ratio
4.43, 95 % confidence interval 1.47–13.39, p <0.01).
Second malignancy
22 (17 %) patients developed second cancers during
follow-up. Lung cancer was the most common site of a
new primary tumour, occurring in 8 (36 %) patients.
Details of second malignancies are listed in Table 3.
Toxicity outcomes
Documented RTOG grade 3 skin toxicity occurred in 9
(6.8 %) of patients. RTOG grade 3 mucositis requiring en-
teral nutrition (via nasogastric tube feeding in all cases)
occurred in 13 (9.8 %) patients. No deaths occurred within
90 days of completion of radiotherapy. Documented late
toxicity in included post-cricoid stenosis in one patient
managed with repeated dilatations, anterior glottic web-
bing in one patient, and one patient requiring a tracheos-
tomy 3 years post radiotherapy with progressive laryngeal
symptoms and no evidence of disease recurrence. No pa-
tients required long term enteral feeding.
Discussion
Dose fractionation along with overall treatment time are
expected to be key factors in the outcomes of definitive
radiotherapy for early glottis cancer. Schedules with
shortened overall treatment times have the potential ad-
vantage of minimising the impact of accelerated repopula-
tion. Overall treatment time is known to be related to
locoregional control for head and neck cancers; an ana-
lysis of two trials suggested that in node negative larynx
cancer an additional dose of 0.8Gy/day is required to con-
trol tumour with increased treatment time [22]. An accel-
eration in treatment time can be achieved by either
hypofractionation or hyperfractionation with multiple
treatments per day. As previously described [21], radiobio-
logical modelling based upon the linear quadratic model
suggests similar log10 cell kill (as shown in Table 4) and a
lower late-effects BED for a schedule of 55G in 20 frac-
tions over 26 days compared with a conventionally frac-
tionated schedule of 70Gy in 35 fractions over 46 days.
For late effects (using an α/β of 3Gy for late responding
tissues) the BED3 for a schedule of 55Gy in 20 fractions is
105.4Gy and for a schedule of 70Gy in 35 fractions is
116.6Gy respectively. This suggests a potential therapeutic
gain for hypofractionation. Hypofractionation is a particu-
larly appealing strategy for early glottic cancers with the
limited size of the target volume and the consequently
limited mucosal volume.
Table 2 Recurrence patterns and management
Outcomes N (% of total)
Complete response to radiotherapy 131 (99)
Persistent disease 1 (1)
Local Recurrence only 14 (11)
At primary subsite 13 (10)
Near primary subsite 1 (1)
Regional recurrence only 3 (2)
Combined locoregional recurrence 3 (2)
Salvage surgery 18 (14)
Laser cordotomy 2 (2)
Total laryngectomy ± neck diss. 13 (10)
Radical neck dissection 1 (1)
Radical neck dissection + brachytherapy 2 (2)
Fig. 1 Kaplan Meier curves showing 5-year a local control, b cause specific survival and c overall survival
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Our single institution series reports on outcomes using
a schedule of 55Gy in 20 fractions with 2.75Gy per frac-
tion with high rates of local control even after prior failure
of laser therapy with acceptable toxicity. A high propor-
tion of our series (48 % of patients) had T2 disease (which
in the 2002 and 2007 TNM classifications [23, 24] in-
cludes the T2a and T2b stages of the 1998 classification
[25]. Table 4 provides a comparison of 5-year local control
rates from multiple studies [8, 11, 12, 16, 26–30] employ-
ing hypofractionated radiotherapy schedules for T1N0
and T2N0 squamous cell carcinoma of the glottis. Direct
comparisons are limited by the heterogenous nature of
the schedules used, variability in whether studies are ex-
clusively of T1N0 disease or also include T2N0 disease
and variable outcome measures. Similarly, Chera et al.
previously documented 5-year local control rates from
eleven large previous studies using a mix of conventional
and hypofractionated schedules using the 1998 TNM clas-
sification which subdivides T2 disease into T2a and T2b
based upon cord mobility. For T1a, T1b and T2a and T2b
disease 5-year local control rates were reported in the
order of 82–94 %, 80–93 %, 62–94 % and 23–73 % re-
spectively; of note for T2a disease only a single study re-
ported 5–year local control rates of >80 % [16]. By
comparison, in our series 5-year local control rates were
91.8 %, 81.6 % and 80.9 % for T1a, T1b and T2 disease.
These results appear particularly promising for T2
disease. Within the T2 group, five patients had supra-
and subglottic extension and had an inferior outcome.
Treatment failures were predominantly local with high
rates of successful surgical salvage; lymph node recurrence
was uncommon.
Hypofractionated regimens are widely used within the
UK [13]. Despite this, few institutions have reported the
use of accelerated hypofractionation with larger fraction
sizes larger than 2.5Gy; in particular there is a paucity of
data to support the use of these schedules for T2 dis-
ease. Gowda et al. [12] reported combined data from the
Christie Hospital and Royal Marsden Hospital of 200 pa-
tients with T1 glottic cancer treated between 1989 and
1997 with 50–52.5Gy in 16 fractions over 3 weeks (frac-
tion size 3.12–3.28Gy); overall 5–year local control was
93 %. Cheah et al. [11] reported the experience in
Birmingham of a regimen of 50Gy in 16 fractions over 3
weeks in the treatment of 100 patients with T1N0 glottic
carcinoma; overall 5-year locoregional control was 88 %.
It should be noted that these series were restricted to
T1N0 disease. Laskar et al. [28] also reported on accept-
able local control of T1 glottic carcinoma with 50–55Gy
in 15–16 fractions in a series comparing multiple frac-
tionation schedules from a single institution. Short et al.
[29] reported a retrospective comparison between 1986
and 1998 which included both T1/2 glottic carcinoma
treated with 60–66Gy in 30–33 fractions compared with
52.5–55Gy in 20 fractions over 4 weeks in a later cohort
of 94 patients (30 % T2 disease); for T1 disease, 5-year
locoregional control was 75 % versus 95 % in favour of
hypofractionation, although no difference was observed
in for T2 disease (5-year locoregional control rates of
80 % versus 81 % respectively). A report examining the
prognostic impact of pre-treatment haemoglobin concen-
tration from Princess Margaret Hospital in Canada docu-
mented a 5-year relapse free rate of 81 % in 735 patients
who received a standard dose of 50Gy in 20 fractions over
4 weeks, however in the subset with T2 disease 5-year re-
lapse free rate was lower at 69 % [31].
Several randomised trials have examined the use of
more modestly hypofractionationed schedules, using
2.25Gy per fraction. A Japanese trial by Yamazaki et al.
randomised 180 T1 glottic cancer patients to 60–66Gy
in 30–33 fractions (2Gy per fraction) versus 56.25–63Gy
in 25–28 fractions (2.25Gy per fraction) (higher dose in
both arms for tumours involving >2/3 of one cord); 5
year local control was 77 % versus 92 % (p = 0.004); the
authors’ conclusion was that the higher dose per fraction
of 2.25Gy with a shorter overall treatment time offered
superior local control [8]. A randomised controlled trial
from South Korea [26] compared a conventional 2Gy
per fraction arm (66Gy in 33 fractions for T1 and 70Gy
in 35 fractions for T2) with a hypofractionated 2.25Gy
per fraction arm (63Gy in 28 fractions for T1 and
67.5Gy in 30 fractions for T2); the study closed prema-
turely due to poor accrual with 156 of a planned 282 pa-
tients; 5-year local progression free survival was 77.8 %
versus 88.5 % (non-significant).
In addition, several retrospective series report on the
use of 2.25Gy fraction sizes. A large retrospective series
of 585 patients treated at the University of Florida for
T1/2 glottic cancer was recently reported; 61 % of patients
received ≥2.25Gy/fraction. As detailed in the paper, overall
Table 3 Second malignancies in study group
Diseasea Incidence
Lung carcinoma 8 (6 %)
Gastric carcinoma 3 (2 %)
Colon carcinoma 2 (2 %)
Lymphoma 2 (2 %)
Lip, skin carcinoma 2 (2 %)
Hypopharynx 2 (2 %)
Soft tissue carcinosarcomab 1 (1 %)
Renal cell carcinoma 1 (1 %)
Heamatologic malignancy 1 (1 %)
Adrenal tumor 1 (2 %)
Ovarian carcinoma 1 (1 %)
aTwo patients had two malignancies
bIn-field in right neck, 6 years post-radiotherapy
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Table 4 Five year local control rates from studies employing hypofractionated radiotherapy for T1N0 and T20 squamous cell carcinoma of the glottis
Author/year No. of patients Dose (5 days/week daily fractionation
unless stated)
Fraction
size
OTT tBED Follow up/
years
5 year LC T1a 5 year LC T1b 5 year LC
T2
Current series 132 (n = 68 T1) 55Gy in 20 2.75 26 67.0 6 91.8 % 81.6 % 80.9 %
Moon et al. 2014 [26] 156 (n = 139 T1) RCT: 5.6 5 years Local PFS
Conventional arm
(n = 82):
T1/2:
77.8 % conv
66 in 33 for T1 2Gy 44 62.3 88.5 % hypo
70Gy in 35 for T2 47 64.7
Hypofractionated arm
(n = 74):
T1 only:
80.3 % conv
63Gy in 28 (T1) 67.5Gy
in 30 for T2
2.25Gy 38 64.9 90.1 % hypo
40 68.8
T1a only: 76.7 % conv
93 % hypo
Kim et al. 2012 [27] 157
(n=125 T1 only)
70Gy in 35 (n = 64 pts) 2Gy 47 64.7 7.1 All T1
83 % 63 %
67.5Gy in 30 (n = 93) 2.25Gy 40 68.8 3.8 95 % 61 %
Laskar et al. 2012 [28] 652 (T1 only) 50Gy in 15 3.3Gy 19 68.9 5 All T1: 90.6 % >3Gy per fraction
86.8Gy <3Gy per fraction (NS difference
between fractionation schedules)55Gy in 16 3.43Gy 22 73.9
60Gy in 24 2.5Gy 32 67.3
62.5 in 25 2.5Gy 33 69.6
Jamshed et al. 2011 [30] 87 (n = 83 T1) 55Gy in 20 2.75 26 67.0 2.6 LRC 95 % LRC 88 % n/a
Chera et al. 2009 [16] 585 (n = 325) 63Gy in 28 (T1) 2.25Gy 38 64.9 12 94 % 93 % T2a 80 %
65.25Gy in 29 (T2) 39 66.8 T2b 70 %
(39 % of series includes other schedules
including hyperfractionation)
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Table 4 Five year local control rates from studies employing hypofractionated radiotherapy for T1N0 and T20 squamous cell carcinoma of the glottis (Continued)
Cheah et al. 2009 [11] 100 (T1 only) 50Gy in 16 fractions 3.125Gy 22 65.6 7 90 % 85 % N/A
Short et al. 2006 [29] 145 (n = 102 T1) 60–66Gy in 30–33 (n = 51) 2 40–44 58.1–62.3 4.9 All T1
LRC 75 % conv
LRC 80 %
(conv)
52.5-55Gy in 20 (n = 94) 2.625–2.75 26 63.2–67.0 LRC 91 % hypo LRC 81 %
(hypo)
Yamazaki et al. 2006 [8] 180 (T1 only) RCT: 60–66Gy in 30–33 Not stated All T1
(66Gy if >2/3 of cord) (n = 89) 2Gy 40–44 58.1–62.3 LC 77 % conv
56.25Gy in 25 or 63Gy in 28
(>2/3cord) (n = 91)
2.25Gy 33–38 60.4–64.9 LC 92 % hypo
Gowda 2003 [12] 200 (T1 only) 50–52.5Gy in 16 3.12–3.28Gy 22 65.6–68.7 5.8 93.1 % 89.1 %
Conv = conventional fractionation
Hypo = hypofractionated
LC = local control
LRC = locoregional control
OTT = overall treatment time
PFS = progression free survival
tBED = tumour biologically effective dose
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local control rates compared favourably with other re-
ported series with 5 year local control rates of T1a 94 %,
T1b 93 %, T2a 80 % and T2b 70 % (using the 1998 5th
edition of the American Joint Committee on Cancer
(AJCC) staging guidelines for early-stage SCCA of the
glottis [25]), and on multivariate analysis overall treatment
time >41 days was associated with inferior outcome. A
series of 398 patients treated at the University of Califor-
nia was reported in 1997, including a range of fraction
sizes; 5-year local control was 85 % for T1 and 70 % for
T2. Fraction size of ≥2.25Gy was a significant factor in
local control for T2 tumors [9]. Increased fraction size ap-
peared beneficial independent of total dose and treatment
time [9, 32]. Kim et al. [27] reported a retrospective
analysis outcomes of a series of 157 patients with T1/
2 glottic carcinomas treated with either 70Gy in 35
fractions or 67.5Gy in 30 fractions; disease free sur-
vival was significantly superior in the 2.25Gy/fraction
arm. Overall this increasing body of evidence have
established hypofractionation as the standard of care
for definitive radiotherapy treatment of T1/2 glottic
carcinomas, providing increased local control with ac-
ceptable toxicity.
In addition to the radiobiological perspective, the use of
hypofractionation is appealing from both health econom-
ics and patient perspectives. Hypofractionated radiother-
apy reduces both treatment time, number of fractions
delivered and consequently cost; this eases the burden of
treatment upon institutions. In addition, patients poten-
tially benefit from the convenience of shorter schedules
with fewer treatment visits required.
Hyperfractionation is an alternative approach to accel-
erate treatment schedules. The recently reported RTOG
9512 hyperfractionation study of 250 patients with T2N0
glottic carcinoma recruited between 1996 and 2003
compared a conventional arm of 70Gy in 35 daily frac-
tions with 79.2Gy in 66 fractions of 1.2Gy bi-daily frac-
tions; 5-year local control rate was 70 % versus 78 %
(non-significant, p = 0.14) [10]. The 5-year local control
rates in our series of 80.9 % is superior that achieved in
the hyperfractionation arm of this study. The absence of
a significant benefit of hyperfractionation, along with the
practical challenges of implementing bi-daily treatment,
suggests that hyperfractionation will not replace hypo-
fractination as a standard treatment approach.
In our series, we found an 17 % of patients developed an-
other primary cancer. This is similar to the rate of 21 % re-
ported by Cheah et al. [11], 22 % by Khan et al. [33], 20 %
and 22 % by Franchin et al. [34]. In the RTOG 9512 study,
20 % of deaths were due to a second primary [10]. Since
smoking is the major aetiological factor for larynx carcin-
oma, these data serve to emphasise the importance of
smoking cessation interventions and highlight this a poten-
tial group of patients for targeting screening interventions.
There are several limitations to our series. In common
with other series, it is difficult to determine whether the
‘recurrence’ on long term follow up represents local
failure or the development of a new primary; for the
purposes of analysis we have classified these cases as re-
currence Comparison with other series is complicated
by the range of differing outcome measures reported,
differing proportions of T1 versus T2 disease, and some
previous series dividing T2 disease into T2a and T2b
according to older versions of the TNM classification
[16]. In addition to tumour control, voice quality is an
important outcome in the treatment of larynx cancer,
and in view of the retrospective nature of this analysis,
no data is available. A previous study of 25 patients has
previously shown voice outcomes improved over period
12 months compared with pre-treatment following treat-
ment with a hypofractionated schedule (50Gy in 16 frac-
tions) [35]. In common with other series, late toxicity is
patchily documented. There is current interest in the po-
tential for intensity modulated radiotherapy techniques to
offer carotid artery sparing [36]; it was not possible to
reliably document the long term risk of cerebrovascular
events with conventional radiotherapy in this series.
Conclusion
In summary, the optimum fraction size/dose and treat-
ment time for early glottic cancer has yet to be established,
although in the published literature hypofractionated ac-
celerated radiotherapy schedules appear to be highly ef-
fective. This series demonstrates that a schedule of 55Gy
in 20 fractions over 4 weeks offers high rates of local con-
trol with acceptable long term toxicity for both T1 and T2
disease.
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